Trial Profile
Neoadjuvant Treatment With the Combination of Vemurafenib, Cobimetinib and Atezolizumab in Limited Metastasis of Malignant Melanoma (AJCC Stage IIIC/IV) and Integrated Biomarker Study: a Single Armed, Two Cohort, Phase II EADO Trial NEO-VC
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 18 Mar 2024
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary) ; Cobimetinib (Primary) ; Vemurafenib (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- Acronyms NEO-VC
- 29 Jan 2021 Status changed from recruiting to discontinued.
- 30 May 2020 This trial has been Discontinued in Germany according to European Clinical Trials Database record.
- 30 Oct 2019 Planned End Date changed from 1 Sep 2020 to 1 Feb 2021.